Publication:
Tumor-derived ligands trigger tumor growth and host wasting via differential MEK activation

dc.contributor.coauthorSong, Wei
dc.contributor.coauthorHong, Shangyu
dc.contributor.coauthorHu, Yanhui
dc.contributor.coauthorWang, Xiaohui
dc.contributor.coauthorBinari, Richard
dc.contributor.coauthorTang, Hong-Wen
dc.contributor.coauthorChung, Verena
dc.contributor.coauthorBanks, Alexander S.
dc.contributor.coauthorSpiegelman, Bruce
dc.contributor.coauthorPerrimon, Norbert
dc.contributor.departmentDepartment of Molecular Biology and Genetics
dc.contributor.departmentDepartment of Molecular Biology and Genetics
dc.contributor.kuauthorKır, Serkan
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.yokid274185
dc.date.accessioned2024-11-09T23:53:54Z
dc.date.issued2019
dc.description.abstractInteractions between tumors and host tissues play essential roles in tumor-induced systemic wasting and cancer cachexia, including muscle wasting and lipid loss. However, the pathogenic molecular mechanisms of wasting are still poorly understood. Using a fly model of tumor-induced organ wasting, we observed aberrant MEK activation in both tumors and host tissues of flies bearing gut-yki(3SA) tumors. We found that host MEK activation results in muscle wasting and lipid loss, while tumor MEK activation is required for tumor growth. Strikingly, host MEK suppression alone is sufficient to abolish the wasting phenotypes without affecting tumor growth. We further uncovered that yki(3SA) tumors produce the vein (vn) ligand to trigger autonomous Egfr/MEK-induced tumor growth and produce the PDGF- and VEGF-related factor 1 (Pvf1) ligand to non-autonomously activate host Pvr/MEK signaling and wasting. Altogether, our results demonstrate the essential roles and molecular mechanisms of differential MEK activation in tumor-induced host wasting.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipAmerican Diabetes Association [1-16-PDF-108]
dc.description.sponsorshipNIH [R01AR057352, P01CA120964] We thank Arpan Ghosh, Ben Ewen-Campen, Pedro Saavedra, and Charles Xu for comments
dc.description.sponsorshipTian Xu and Xianjue Ma for eyFLP1-FRT and Ras<SUP>V12</SUP> scrib<SUP>1</SUP> lines
dc.description.sponsorshipMichael J. Galko for Pvf1-null mutant
dc.description.sponsorshipBenny Shilo for Pvf1 antibody
dc.description.sponsorshipand Hugo Stocker for ILP2 antibody. This work was supported in part by the American Diabetes Association (1-16-PDF-108). Work in the Perrimon lab is supported by NIH grants R01AR057352 and P01CA120964. N.P. is an Investigator of the Howard Hughes Medical Institute.
dc.description.volume48
dc.identifier.doi10.1016/j.devcel.2018.12.003
dc.identifier.eissn1878-1551
dc.identifier.issn1534-5807
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85060285204
dc.identifier.urihttp://dx.doi.org/10.1016/j.devcel.2018.12.003
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15103
dc.identifier.wos456815400014
dc.keywordsCancer cachexia
dc.keywordsFat-body
dc.keywordsExpression
dc.keywordsReceptor
dc.languageEnglish
dc.publisherCell Press
dc.sourceDevelopmental Cell
dc.subjectCell biology
dc.subjectDevelopmental biology
dc.titleTumor-derived ligands trigger tumor growth and host wasting via differential MEK activation
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0001-8722-9913
local.contributor.kuauthorKır, Serkan
relation.isOrgUnitOfPublicationaee2d329-aabe-4b58-ba67-09dbf8575547
relation.isOrgUnitOfPublication.latestForDiscoveryaee2d329-aabe-4b58-ba67-09dbf8575547

Files